Biohaven Ltd. Common Shares (BHVN)
BHVN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BHVN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001935979 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Virgin Islands, British |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Going Concern In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued." | 10-Q 2026-10-29 |
| Cash and burn | $95.8M cash; operating cash flow -$118.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 151,058,781 (2026-10-26); 105,855,155 a year earlier; 80,233,656 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Stamford, Connecticut, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $30.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$129.3M | -$106.9M | $95.8M | No debt tags | Needs four quarters | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | Not filed | -$137.3M | -$85.1M | $238.0M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | Not filed | -$130.5M | -$149.9M | $273.1M | No debt tags | Needs four quarters | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | Not filed | -$145.6M | -$130.7M | $230.0M | No debt tags | Needs four quarters | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | Not filed | -$173.4M | -$145.7M | $184.8M | No debt tags | Needs four quarters | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | Not filed | -$198.1M | -$167.9M | $165.8M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | Not filed | -$221.7M | -$165.1M | $98.4M | No debt tags | Needs four quarters | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | Not filed | -$186.8M | -$170.7M | $99.1M | No debt tags | Needs four quarters | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-04 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-03-13 |
Source: SEC EDGAR submissions feed, 284 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.6% |
| 1 month | +21.0% |
| 3 months | -6.9% |
| Year to date | +22.4% |
| 1 year | +71.0% |
| From 52-week high | -18.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
| AUPH | Aurinia Pharmaceuticals Inc | $15.48 | -1.59% | $2.1B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| SDGR | Schrodinger Inc. | $27.36 | -7.35% | $2.1B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier